Background
Methods
Study populations
axSpA (n = 110) | PsA (n = 101) | Control | |
---|---|---|---|
Male sex, % | 72 % | 59 % | |
Age, years | 36.6 (35.3–38.0) | 37.0 (35.6–38.5) | |
BMI, kg/m2
| 25.5 (24.8–26.3) | 27.4 (26.2–28.5) | |
Smoker, % | 36 % | 35 % | |
HLA-B27 positive, % | 87 % | 20 % | |
Disease duration, years | 6.4 (5.4–7.5) | 6.7 (5.6–7.8) | |
VAS | |||
Patient global | 34 (29–39) | 39 (34–45) | |
Patient pain | 32 (27–37) | 32 (27–37) | |
Patient fatigue | 40 (34–45) | 43 (37–49) | |
Physician global | 4 [1–16] | 3 [1–14] | |
BASDAI | 31 (26–35) | 36 (31–41) | |
BASFI | 23 (19–27) | 27 (22–32) | |
BASMI | 10 [0–20] | 10 [0–10] | |
ASDAS (CRP) | 2.0 (1.8–2.3) | 2.1 (1.9–2.4) | |
Swollen joints, % | 9 % | 38 % | |
hs-CRP, mg/dl | 3 [1–7] | 3 [1–9] | |
Pro-C2, ng/ml | 1.11 [0.67-1.64] | 1.03 [0.53-1.47] | 0.30 [0.16-0.41] |
Col-X, ng/ml | 0.45 [0.28-0.67] | 0.42 [0.31-0.72] | 0.33 [0.31-0.45] |
Biomarker measurements
Statistics
Results
Patient demographics
Cartilage turnover is increased in axSpA and PsA
Pro-C2 associations
axSpA | PsA | |||||||
---|---|---|---|---|---|---|---|---|
Total (n = 110) | Treatment-naïve (n = 34) | Currently treated, total (n = 63) | Previously treated (n = 13) | Total (n = 101) | Treatment-naïve (n = 13) | Currently treated, total (n = 76) | Previously treated (n = 12) | |
Age | ns | ns | ns | ns | ns |
r = −0.55 | ns | ns |
p = −0.051 | ||||||||
BMI | ns | ns | ns | ns | ns |
r = 0.60 | ns | ns |
p = 0.032 | ||||||||
Disease duration | ns | ns | ns |
r = 0.54 | ns |
r = 0.55 | ns | ns |
p = 0.030 |
p = 0.052 | |||||||
ASDAS | ns |
r = 0.45 | ns | ns | ns | ns | ns | ns |
p = 0.008 | ||||||||
HAQ | ns | ns |
r = 0.47 | ns |
r = −0.34 | ns |
r = −0.35 | ns |
p = 0.010 |
p = 0.004 |
p = 0.008 | ||||||
Sex | ns | ns | ns | ns | ns | ns | ns | ns |
BASDAI | ns | ns | ns | ns | ns | ns | ns | ns |
BASFI | ns | ns |
r = −0.30 | ns | ns | ns | ns | ns |
p = 0.008 | ||||||||
SJC68 | ns | ns | ns | ns | ns | ns | ns |
r = −0.92 |
p = 0.0001 | ||||||||
TJC68 | ns | ns | ns | ns | ns | ns | ns |
r = −0.89 |
p = 0.0003 |
C-Col10 associations
axSpA | PsA | |||||||
---|---|---|---|---|---|---|---|---|
Total (n = 110) | Treatment-naïve (n = 34) | Currently treated (n = 63) | Previously treated (n = 13) | Total (n = 101) | Treatment-naïve (n = 13) | Currently treated (n = 76) | Previously treated (n = 12) | |
Age | ns | ns | ns | ns | ns | ns | ns | ns |
BMI | ns | ns | ns | ns | ns | ns | ns | ns |
Disease duration | ns |
r = −0.38 | ns | ns | ns | ns | ns | ns |
p = 0.027 | ||||||||
ASDAS | ns | ns | ns | ns | ns | ns | ns | ns |
Alcohol consumption | ns | ns | ns |
r = −0.60 | ns | ns | ns | ns |
p = 0.022 | ||||||||
HAQ | ns | ns | ns | ns | ns | ns | ns | ns |
Sex | ns | ns |
r = 0.30 | ns | ns | ns | ns | ns |
p = 0.021 | ||||||||
BASDAI | ns | ns | ns | ns | ns | ns | ns | ns |
SJC68 | ns |
r = −0.36 | ns | ns | ns | ns | ns | ns |
p = −0.037 | ||||||||
TJC68 |
r = −0.20 | ns | ns | ns | ns | ns | ns |
r = −0.73 |
p = 0.043 |
p = 0.011 |
Discriminative power of Pro-C2 and C-Col10
AUC (95 % CI) | Youden index | Sensitivity | Specificity | |
---|---|---|---|---|
Pro-C2 | ||||
Healthy vs. axSpA | 0.85 (0.79–0.89) | 0.58 | 87.9 | 70.6 |
Healthy vs. PsA | 0.81 (0.75–0.86) | 0.51 | 92.7 | 58.8 |
axSpA vs. PsA | 0.54 (0.47–0.61) | 0.13 | 17.43 | 95.2 |
C-Col10 | ||||
Healthy vs. axSpA | 0.58 (0.51–0.65) | 0.18 | 67.0 | 51.4 |
Healthy vs. PsA | 0.61 (0.54–0.67) | 0.21 | 69.7 | 51.4 |
axSpA vs. PsA | 0.52 (0.45–0.59) | 0.11 | 94.5 | 16.8 |